Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout

Eli Lilly spends more of its GLP-1 cash, Humira's masterclass in monopoly, and more updates from The Readout

Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout